Shiyan Key Laboratory of Natural Medicine Nanoformulation Research, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei, China.
Department of Pulmonary and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Phytother Res. 2024 Aug;38(8):3856-3876. doi: 10.1002/ptr.8242. Epub 2024 May 18.
Enhancement of malignant cell immunogenicity to relieve immunosuppression of lung cancer microenvironment is essential in lung cancer treatment. In previous study, we have demonstrated that dihydroartemisinin (DHA), a kind of phytopharmaceutical, is effective in inhibiting lung cancer cells and boosting their immunogenicity, while the initial target of DHA's intracellular action is poorly understood. The present in-depth analysis aims to reveal the influence of DHA on the highly expressed TOM70 in the mitochondrial membrane of lung cancer. The affinity of DHA and TOM70 was analyzed by microscale thermophoresis (MST), pronase stability, and thermal stability. The functions and underlying mechanism were investigated using western blots, qRT-PCR, flow cytometry, and rescue experiments. TOM70 inhibition resulted in mtDNA damage and translocation to the cytoplasm from mitochondria due to the disruption of mitochondrial homeostasis. Further ex and in vivo findings also showed that the cGAS/STING/NLRP3 signaling pathway was activated by mtDNA and thereby malignant cells underwent pyroptosis, leading to enhanced immunogenicity of lung cancer cells in the presence of DHA. Nevertheless, DHA-induced mtDNA translocation and cGAS/STING/NLRP3 mobilization were synchronously attenuated when TOM70 was replenished. Finally, DHA was demonstrated to possess potent anti-lung cancer efficacy in vitro and in vivo. Taken together, these data confirm that TOM70 is an important target for DHA to disturb mitochondria homeostasis, which further activates STING and arouses pyroptosis to strengthen immunogenicity against lung cancer thereupon. The present study provides vital clues for phytomedicine-mediated anti-tumor therapy.
增强恶性细胞的免疫原性以缓解肺癌微环境的免疫抑制在肺癌治疗中至关重要。在之前的研究中,我们已经证明,青蒿素(DHA)是一种植物药,可有效抑制肺癌细胞并增强其免疫原性,但其细胞内作用的初始靶点尚不清楚。本深入分析旨在揭示 DHA 对肺癌线粒体膜中高表达的 TOM70 的影响。通过微量热泳动(MST)、蛋白酶稳定性和热稳定性分析了 DHA 和 TOM70 的亲和力。使用 Western blot、qRT-PCR、流式细胞术和挽救实验研究了功能和潜在机制。由于线粒体稳态的破坏,TOM70 抑制导致 mtDNA 损伤和从线粒体向细胞质易位。进一步的外和体内研究结果还表明,cGAS/STING/NLRP3 信号通路被 mtDNA 激活,从而导致恶性细胞发生细胞焦亡,从而在存在 DHA 的情况下增强肺癌细胞的免疫原性。然而,当 TOM70 被补充时,DHA 诱导的 mtDNA 易位和 cGAS/STING/NLRP3 动员被同步减弱。最后,证明 DHA 在体外和体内均具有很强的抗肺癌功效。总之,这些数据证实 TOM70 是 DHA 扰乱线粒体稳态的重要靶标,这进一步激活了 STING 并引起细胞焦亡,从而增强了对肺癌的免疫原性。本研究为植物药介导的抗肿瘤治疗提供了重要线索。
Ecotoxicol Environ Saf. 2024-10-15
J Cancer Res Clin Oncol. 2024-10-14
Mol Cancer. 2025-2-26